Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights Genetics Investing
Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP Genetics Investing
Myriad Presents Two New Studies at the Western Section of the American Urological Association Genetics Investing
Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA Genetics Investing
